Conditional expression of oncogenic K-ras from its endogenous promoter induces a myeloproliferative disease
Open accessThe DOI matches its Crossref record; 73 of the 73 references it cites were found in a registry or an index.
Abstract
Oncogenic ras alleles are among the most common mutations found in patients with acute myeloid leukemia (AML). Previously, the role of oncogenic ras in cancer was assessed in model systems overexpressing oncogenic ras from heterologous promoters. However, there is increasing evidence that subtle differences in gene dosage and regulation of gene expression from endogenous promoters play critical roles in cancer pathogenesis. We characterized the role of oncogenic K-ras expressed from its endogenous promoter in the hematopoietic system using a conditional allele and IFN-inducible, Cre-mediated recombination. Mice developed a completely penetrant myeloproliferative syndrome characterized by leukocytosis with normal maturation of myeloid lineage cells; myeloid hyperplasia in bone marrow; and extramedullary hematopoiesis in the spleen and liver. Flow cytometry confirmed the myeloproliferative phenotype. Genotypic and Western blot analysis demonstrated Cre-mediated excision and expression, respectively, of the oncogenic K-ras allele. Bone marrow cells formed growth factor-independent colonies in methylcellulose cultures, but the myeloproliferative disease was not transplantable into secondary recipients. Thus, oncogenic K-ras induces a myeloproliferative disorder but not AML, indicating that additional mutations are required for AML development. This model system will be useful for assessing the contribution of cooperating mutations in AML and testing ras inhibitors in vivo.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Expression of the most common KRAS mutation (G12D) in mouse hematopoietic cells causes a fatal myeloproliferative neoplasm (MPN).6,7”
From USP22 deficiency leads to myeloid leukemia upon oncogenic Kras activation through a PU.1-dependent mechanism (2018) · cites this paper as [7]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a
Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D., & Lowe, S. W. (1997) · Cell · doi:10.1016/s0092-8674(00)81902-9 · Cited by 5,218
A clonogenic common myeloid progenitor that gives rise to all myeloid lineages
Akashi, K., Traver, D., Miyamoto, T., & Weissman, I. L. (2000) · Nature · doi:10.1038/35004599 · Cited by 2,617 · cited 3×
“Myeloid progenitors were distinguished as Lin–Sca-1–c-Kit+CD34+FcγRII/IIIlo common myeloid progenitors (CMPs), Lin–Sca-1–cKit+CD34+FcγRII/IIIhi granulocyte-monocyte progenitors (GMPs), and Lin–Sca-1–c-Kit+CD34–FcγII/IIIlo megakaryocyte-erythrocyte progenitors (MEPs) (43).”
BackgroundSelf-citationAnalysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras
Jackson, E. L., Willis, N., Mercer, K., Bronson, R. T., Crowley, D., Montoya, R., Jacks, T., & Tuveson, D. A. (2001) · Genes & Development · doi:10.1101/gad.943001 · Cited by 1,898 · cited 4×
“floxed LSL–K-ras G12D allele (38) containing a transcriptional ter-”
BackgroundResultInfluentialSelf-citationDaley, G. Q., Van Etten, R. A., & Baltimore, D. (1990) · Science · doi:10.1126/science.2406902 · Cited by 1,756 · cited 4×
“The Journal of Clinical Investigation | February 2004 | Volume 113 | Number 4 537 Growth factor–independent colony-forming activity of bone marrow cells has also been described in TEL-JAK2 and BCR/ABL murine bone marrow transplant models (51, 52).”
InfluentialInducible Gene Targeting in Mice
Kühn, R., Schwenk, F., Aguet, M., & Rajewsky, K. (1995) · Science · doi:10.1126/science.7660125 · Cited by 1,641 · cited 4×
“In studies of Mx1-Cre–mediated recombination of a floxed DNA polymerase β gene, pI-pC treatment yielded high recombination efficiencies in hematopoietic tissues (liver, 100%; spleen, 94%; and thymus, 40%) and lower levels in nonhematopoietic tissues such as heart, kidney, lung, and duodenum (37).”
BackgroundMethodInfluentialThe roles of FLT3 in hematopoiesis and leukemia
Gilliland, D. G., & Griffin, J. D. (2002) · Blood · doi:10.1182/blood-2002-02-0492 · Cited by 1,558 · cited 1×
“Examples of tyrosine kinase gain-of-function mutations in AML include FLT3 activation loop point mutations, FLT3 juxtamembrane region internal tandem duplications (ITDs) (14), C-KIT point mutations (15), and the tyrosine kinase fusion products of chromosomal translocations such as TEL/ TRKC associated with t(12;15) (1…”
BackgroundSelf-citationSomatic activation of the K-ras oncogene causes early onset lung cancer in mice
Johnson, L., Mercer, K., Greenbaum, D., Bronson, R. T., Crowley, D., Tuveson, D. A., & Jacks, T. (2001) · Nature · doi:10.1038/35074129 · Cited by 1,179 · cited 2×
“Papillomas and thymic lymphomas have been previously observed in 30% of adenovirus-Cre–treated oncogenic K-ras mice (40).”
BackgroundMethodSelf-citationSong, W.-J., Sullivan, M. G., Legare, R. D., Hutchings, S., Tan, X., Kufrin, D., Ratajczak, J., Resende, I. C., Haworth, C., Hock, R., et al. (1999) · Nature Genetics · doi:10.1038/13793 · Cited by 1,100 · cited 2×
“KM – 8–83 (35) 34–53 (41) 156–885 (583) 70–1,271 (540) 704–2,777 (1491) MPD n = 6 n = 6 n = 6 n = 8 n = 8”
BackgroundSelf-citationRodriguez-Viciana, P., Warne, P. H., Khwaja, A., Marte, B. M., Pappin, D., Das, P., Waterfield, M. D., Ridley, A., & Downward, J. (1997) · Cell · doi:10.1016/s0092-8674(00)80226-3 · Cited by 1,061
Sinn, E., Muller, W., Pattengale, P., Tepler, I., Wallace, R., & Leder, P. (1987) · Cell · doi:10.1016/0092-8674(87)90449-1 · Cited by 792 · cited 1×
“Transgenic mice expressing viral H-ras from the MMTV promoter/enhancer developed B cell lymphoblastic lymphomas at low frequency (34).”
Background
Cited by
RAS oncogenes: weaving a tumorigenic web
Pylayeva-Gupta, Y., Grabocka, E., & Bar-Sagi, D. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3106 · Cited by 1,789
Hyperactive Ras in developmental disorders and cancer
Schubbert, S., Shannon, K., & Bollag, G. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2109 · Cited by 1,583
Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia
Ren, R. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1567 · Cited by 878
“DH p185 (1-426) p210 (1-902–927) p230 (1–1,176) Y177 Myr GAG BCR F G 1a 1b”
Krebs, A. M., Mitschke, J., Lasierra Losada, M., Schmalhofer, O., Boerries, M., Busch, H., Boettcher, M., Mougiakakos, D., Reichardt, W., Bronsert, P., et al. (2017) · Nature Cell Biology · doi:10.1038/ncb3513 · Cited by 975
Tuveson, D. A., Shaw, A. T., Willis, N. A., Silver, D. P., Jackson, E. L., Chang, S., Mercer, K. L., Grochow, R., Hock, H., Crowley, D., et al. (2004) · Cancer Cell · doi:10.1016/s1535-6108(04)00085-6 · Cited by 798
Self-citationOrigins of tumor-associated macrophages and neutrophils
Cortez-Retamozo, V., Etzrodt, M., Newton, A., Rauch, P. J., Chudnovskiy, A., Berger, C., Ryan, R. J. H., Iwamoto, Y., Marinelli, B., Gorbatov, R., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1113744109 · Cited by 689
“Others have shown the liver as a site for extramedullary myelopoiesis in cancer (35) and other inflammatory processes (29).”
BackgroundThe molecular mechanisms that control thrombopoiesis
Kaushansky, K. (2005) · Journal of Clinical Investigation · doi:10.1172/jci26674 · Cited by 570
Rb Regulates Interactions between Hematopoietic Stem Cells and Their Bone Marrow Microenvironment
Walkley, C. R., Shea, J. M., Sims, N. A., Purton, L. E., & Orkin, S. H. (2007) · Cell · doi:10.1016/j.cell.2007.03.055 · Cited by 424
“Myeloproliferation is generally considered to be hematopoietic intrinsic, and evidence from the overexpression of activated kinase receptors in mouse models is consistent with this view (Araki et al., 2004; Chan et al., 2004; Le et al., 2004).”
Araki, T., Mohi, M. G., Ismat, F. A., Bronson, R. T., Williams, I. R., Kutok, J. L., Yang, W., Pao, L. I., Gilliland, D. G., Epstein, J. A., et al. (2004) · Nature Medicine · doi:10.1038/nm1084 · Cited by 420
Self-citationMullally, A., Lane, S. W., Ball, B., Megerdichian, C., Okabe, R., Al-Shahrour, F., Paktinat, M., Haydu, J. E., Housman, E., Lord, A. M., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.05.015 · Cited by 395
“In general, murine MPN models have been limited in their ability to address questions pertaining to the MPN-initiating cell population because of poor transplantability of the primary disease (Chan et al., 2004, 2009; Braun et al., 2004; Lee et al., 2007).”
BackgroundSelf-citationThe Lkb1 metabolic sensor maintains haematopoietic stem cell survival
Gurumurthy, S., Xie, S. Z., Alagesan, B., Kim, J., Yusuf, R. Z., Saez, B., Tzatsos, A., Ozsolak, F., Milos, P., Ferrari, F., et al. (2010) · Nature · doi:10.1038/nature09572 · Cited by 391
The tyrosine phosphatase Shp2 (PTPN11) in cancer
Chan, G., Kalaitzidis, D., & Neel, B. G. (2008) · Cancer and Metastasis Reviews · doi:10.1007/s10555-008-9126-y · Cited by 382
“Similar effects have been observed utilizing cells from mice with loss of Nf1 [71–75] or expressing a gain-of-function KRas allele [76, 77].”
BackgroundCre-mediated recombination in cell lineages that express the progesterone receptor
Soyal, S. M., Mukherjee, A., Lee, K. Y.-S., Li, J., Li, H., DeMayo, F. J., & Lydon, J. P. (2005) · genesis · doi:10.1002/gene.20098 · Cited by 377
“…importance in epithelial neoplasia (Lydon et al., 1999), crossing the PR-Cre with mice harboring oncogenes preceded by the floxed stop cassette (Chan et al., 2004) could be useful in evaluating the comparative oncogenic potential of various genetic pathways in the female reproductive tract…”
BackgroundA model for RAS mutation patterns in cancers: finding the sweet spot
Li, S., Balmain, A., & Counter, C. M. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0076-6 · Cited by 384
PTPN11 is the first identified proto-oncogene that encodes a tyrosine phosphatase
Chan, R. J., & Feng, G.-S. (2007) · Blood · doi:10.1182/blood-2006-07-028829 · Cited by 371
Developmental and species-divergent globin switching are driven by BCL11A
Sankaran, V. G., Xu, J., Ragoczy, T., Ippolito, G. C., Walkley, C. R., Maika, S. D., Fujiwara, Y., Ito, M., Groudine, M., Bender, M. A., et al. (2009) · Nature · doi:10.1038/nature08243 · Cited by 379
Niemeyer, C. M., Kang, M. W., Shin, D. H., Furlan, I., Erlacher, M., Bunin, N. J., Bunda, S., Finklestein, J. Z., Sakamoto, K. M., Gorr, T. A., et al. (2010) · Nature Genetics · doi:10.1038/ng.641 · Cited by 374
Transcription factors LRF and BCL11A independently repress expression of fetal hemoglobin
Masuda, T., Wang, X., Maeda, M., Canver, M. C., Sher, F., Funnell, A. P. W., Fisher, C., Suciu, M., Martyn, G. E., Norton, L. J., et al. (2016) · Science · doi:10.1126/science.aad3312 · Cited by 373
The RAS/MAPK syndromes: novel roles of the RAS pathway in human genetic disorders
Aoki, Y., Niihori, T., Narumi, Y., Kure, S., & Matsubara, Y. (2008) · Human Mutation · doi:10.1002/humu.20748 · Cited by 365
Genetics of Myeloid Malignancies: Pathogenetic and Clinical Implications
Fröhling, S., Scholl, C., Gilliland, D. G., & Levine, R. L. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.010 · Cited by 353
Self-citationInflammation: A driving force speeds cancer metastasis
Wu, Y., & Zhou, B. P. (2009) · Cell Cycle · doi:10.4161/cc.8.20.9699 · Cited by 327
Mohi, M. G., Williams, I. R., Dearolf, C. R., Chan, G., Kutok, J. L., Cohen, S., Morgan, K., Boulton, C., Shigematsu, H., Keilhack, H., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.01.010 · Cited by 277
Self-citationK-ras as a target for cancer therapy
Friday, B. B., & Adjei, A. A. (2005) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2005.08.001 · Cited by 241
The role of CREB as a proto-oncogene in hematopoiesis and in acute myeloid leukemia
Shankar, D. B., Cheng, J. C., Kinjo, K., Federman, N., Moore, T. B., Gill, A., Rao, N. P., Landaw, E. M., & Sakamoto, K. M. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.02.018 · Cited by 239
“Oncogenic K-ras expression in myeloid progenitor cells has been shown to result in myeloproliferative disease, but not AML (Braun et al., 2004; Chan et al., 2004).”
BackgroundKotecha, N., Flores, N. J., Irish, J. M., Simonds, E. F., Sakai, D. S., Archambeault, S., Diaz-Flores, E., Coram, M., Shannon, K. M., Nolan, G. P., et al. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.08.014 · Cited by 233
“Although these data need to be prospectively validated in a larger cohort study, they suggest that the KRAS mutation, which is phenotypically aggressive in murine models (Braun et al., 2004; Chan et al., 2004), is less dependent upon JAK2-STAT5 signaling than other Ras pathway mutations.”
InfluentialGilad, O., Nabet, B. Y., Ragland, R. L., Schoppy, D. W., Smith, K. D., Durham, A. C., & Brown, E. J. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-2286 · Cited by 228
Koschmieder, S., Göttgens, B., Zhang, P., Iwasaki-Arai, J., Akashi, K., Kutok, J. L., Dayaram, T., Geary, K., Green, A. R., Tenen, D. G., et al. (2005) · Blood · doi:10.1182/blood-2003-12-4369 · Cited by 188
Self-citationTargeting oncogenic Ras signaling in hematologic malignancies
Ward, A. F., Braun, B. S., & Shannon, K. M. (2012) · Blood · doi:10.1182/blood-2012-05-378596 · Cited by 209
Sansom, O. J., Meniel, V., Wilkins, J. A., Cole, A. M., Oien, K. A., Marsh, V., Jamieson, T. J., Guerra, C., Ashton, G. H., Barbacid, M., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0604130103 · Cited by 187
Le, X., Langenau, D. M., Keefe, M. D., Kutok, J. L., Neuberg, D. S., & Zon, L. I. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0611302104 · Cited by 184
Self-citationMercer, K., Giblett, S., Green, S., Lloyd, D., DaRocha Dias, S., Plumb, M., Marais, R., & Pritchard, C. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-2211 · Cited by 179
“myeloproliferative disorders (13), and somatic activation of K-ras in mice using the Mx1-Cre strain induces a similar myeloproliferative disorder (37, 48), indicating that oncogenic B-RAF and RAS target different populations of Mx1-Cre–expressing cells.”
p53 loss promotes acute myeloid leukemia by enabling aberrant self-renewal
Zhao, Z., Zuber, J., Diaz-Flores, E., Lintault, L., Kogan, S. C., Shannon, K., & Lowe, S. W. (2010) · Genes & Development · doi:10.1101/gad.1940710 · Cited by 166
“Expressing oncogenic KrasG12D in the hematopoietic system drives hyperproliferation and differentiation of HSCs and myeloid progenitors, resulting in fatal myeloproliferative disorders (MPDs) (Braun et al. 2004; Chan et al. 2004).”
BackgroundResultInfluentialInamura, K. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19041259 · Cited by 160
“Cellular transformation induced by mutant KRAS is not sufficient to drive carcinogenesis; KRAS-mutated cells require other genomic events, including genomic instability in the context of the inactivation of the TP53 pathway [79,80].”
BackgroundJuvenile myelomonocytic leukemia: who’s the driver at the wheel?
Niemeyer, C. M., & Flotho, C. (2019) · Blood · doi:10.1182/blood-2018-11-844688 · Cited by 169
Recent advances in the pathogenesis and treatment of juvenile myelomonocytic leukaemia
Loh, M. L. (2011) · British Journal of Haematology · doi:10.1111/j.1365-2141.2010.08525.x · Cited by 160
“Animal models have subsequently revealed that Kras mutant mice also develop fatal myeloid disorders that resemble JMML in vivo and in vitro (Braun et al, 2004; Chan et al, 2004).”
BackgroundHematopoiesis and leukemogenesis in mice expressing oncogenic NrasG12D from the endogenous locus
Li, Q., Haigis, K. M., McDaniel, A., Harding-Theobald, E., Kogan, S. C., Akagi, K., Wong, J. C. Y., Braun, B. S., Wolff, L., Jacks, T., et al. (2011) · Blood · doi:10.1182/blood-2010-04-280750 · Cited by 154
Self-citationFunctional analysis of leukemia-associated PTPN11 mutations in primary hematopoietic cells
Schubbert, S., Lieuw, K., Rowe, S. L., Lee, C. M., Li, X., Loh, M. L., Clapp, D. W., & Shannon, K. M. (2005) · Blood · doi:10.1182/blood-2004-11-4207 · Cited by 148
Niemeyer, C. M. (2014) · Haematologica · doi:10.3324/haematol.2014.114595 · Cited by 140
“Similarly, mice expressing oncogenic Kras in hematopoietic cells develop a fatal MPD with 100% penetrance that is characterized by leukocytosis, splenomegaly, and anemia, with death at approximately three months of age.(67,68) There is a puzzling interface between KRAS-associated lymphoproliferative disease (RALD) and…”
BackgroundCritical requirement for Stat5 in a mouse model of polycythemia vera
Yan, D., Hutchison, R. E., & Mohi, G. (2012) · Blood · doi:10.1182/blood-2011-03-345215 · Cited by 131
Caulin, C., Nguyen, T., Lang, G. A., Goepfert, T. M., Brinkley, B. R., Cai, W.-W., Lozano, G., & Roop, D. R. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31721 · Cited by 144
Mutation of Genes Affecting the RAS Pathway Is Common in Childhood Acute Lymphoblastic Leukemia
Case, M. C., Matheson, E. C., Minto, L., Hassan, R., Harrison, C. J., Bown, N. P., Bailey, S., Vormoor, J. H., Hall, A. G., & Irving, J. A. E. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0101 · Cited by 151
Li, L., Piloto, O., Nguyen, H. B., Greenberg, K., Takamiya, K., Racke, F., Huso, D., & Small, D. (2008) · Blood · doi:10.1182/blood-2007-08-109942 · Cited by 130
Genome profiling of chronic myelomonocytic leukemia: frequent alterations of RAS and RUNX1genes
Gelsi-Boyer, V., Trouplin, V., Adélaïde, J., Aceto, N., Remy, V., Pinson, S., Houdayer, C., Arnoulet, C., Sainty, D., Bentires-Alj, M., et al. (2008) · BMC Cancer · doi:10.1186/1471-2407-8-299 · Cited by 126
Plag1 and Plagl2 are oncogenes that induce acute myeloid leukemia in cooperation with Cbfb-MYH11
Landrette, S. F., Kuo, Y., Hensen, K., van Doorn-Khosrovani, S. B. V. W., Perrat, P. N., de Ven, W. J. M. V., Delwel, R., & Castilla, L. H. (2004) · Blood · doi:10.1182/blood-2004-09-3630 · Cited by 144
Mechanisms controlling pathogenesis and survival of leukemic stem cells
Jordan, C. T., & Guzmán, M. L. (2004) · Oncogene · doi:10.1038/sj.onc.1207935 · Cited by 154
“Similarly, recent studies have also employed conditional alleles of leukemic oncogenes in transgenic mice as a means to model early stages of myeloid leukemia (Braun et al., 2004; Chan et al., 2004).”
ResultJuvenile myelomonocytic leukemia and chronic myelomonocytic leukemia
Emanuel, P. D. (2008) · Leukemia · doi:10.1038/leu.2008.162 · Cited by 128
Dasgupta, B., Yi, Y., Hegedűs, B., Weber, J. D., & Gutmann, D. H. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1842 · Cited by 130
Chan, G., Kalaitzidis, D., Usenko, T., Kutok, J. L., Yang, W., Mohi, M. G., & Neel, B. G. (2009) · Blood · doi:10.1182/blood-2008-10-182626 · Cited by 121
Self-citationWang, J., Liu, Y., Li, Z., Du, J., Ryu, M., Taylor, P. R., Fleming, M. D., Young, K. H., Pitot, H. C., & Zhang, J. (2010) · Blood · doi:10.1182/blood-2010-04-281527 · Cited by 121
Loh, M. L., Reynolds, M. G., Vattikuti, S., Gerbing, R. B., Alonzo, T. A., Carlson, E. J., Cheng, J. W., Lee, C. M., Lange, B. J., & Meshinchi, S. (2004) · Leukemia · doi:10.1038/sj.leu.2403492 · Cited by 121
The role of TP53 in acute myeloid leukemia: Challenges and opportunities
Barbosa, K., Li, S., Adams, P. D., & Deshpande, A. J. (2019) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22796 · Cited by 131
“For example, expression of the mutant Kras (Kras) oncogene drives HSC and myeloid progenitor hyperproliferation and differentiation, resulting in fatal myeloproliferative disorders (MPDs).(73,74) However, this mutation alone does not give rise to acute leukemias.”
BackgroundSjogren, A.-K. M., Andersson, K. M. E., Liu, M., Cutts, B. A., Karlsson, C., Wahlstrom, A. M., Dalin, M., Weinbaum, C., Casey, P. J., Tarkowski, A., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30868 · Cited by 117
“In the future, it would be interesting to define the impact of GGTase-I deficiency on other experimental myeloproliferative disease syndromes, for example the one elicited when the KLSL allele is activated by the Mx1-Cre transgene (40, 41).”
BackgroundZebrafish Tumor Assays: The State of Transplantation
Taylor, A. M., & Zon, L. I. (2009) · Zebrafish · doi:10.1089/zeb.2009.0607 · Cited by 123
“27 These results established that oncogenic KRAS alone was not enough to confer self-renewal properties and malignancy in blood cells, in agreement with experiments performed in a mouse model of MPD. 10 Interestingly, ex vivo induction of KRAS before transplantation also induced MPD after primary transplant.”
Van Meter, M. E. M., Díaz-Flores, E., Archard, J. A., Passegué, E., Irish, J. M., Kotecha, N., Nolan, G. P., Shannon, K., & Braun, B. S. (2007) · Blood · doi:10.1182/blood-2006-09-047530 · Cited by 114
Aberrant cytokine signaling in leukemia
Etten, R. A. V. (2007) · Oncogene · doi:10.1038/sj.onc.1210758 · Cited by 121
“P A A uthor M anuscript Table 1 Dysregulated TKs in leukemia Kinase Activating mechanism(s) Leukemia Kinase inhibitor(s) ABL Fusion to BCR Fusion to TEL Fusion to NUP214 or EML1 CML AML, ALL, atypical CML T-ALL Imatinib Dasatinib Nilotinib ALK Fusion to NPM Anaplastic large cell lymphoma (None available) ARG Fusion to…”
BackgroundInfluentialZhang, J., Wang, J., Liu, Y., Sidik, H., Young, K. H., Lodish, H. F., & Fleming, M. D. (2009) · Blood · doi:10.1182/blood-2008-01-134262 · Cited by 102
Oncogenic Kras Initiates Leukemia in Hematopoietic Stem Cells
Sabnis, A. J., Cheung, L. S., Dail, M., Kang, H. C., Santaguida, M. A., Hermiston, M. L., Passegue, E. A., Shannon, K., & Braun, B. S. (2009) · PLoS Biology · doi:10.1371/journal.pbio.1000059 · Cited by 106
“Although early mortality from T-ALL precluded analyzing recipient mice beyond 3 mo, Kras Flk2 LSK cells recapitulate the essential features of MPD seen in the original Mx1-Cre, Kras model [13,14].”
BackgroundWang, J., Liu, Y., Li, Z., Wang, Z., Tan, L. X., Ryu, M.-J., Meline, B., Du, J., Young, K. H., Ranheim, E., et al. (2011) · Blood · doi:10.1182/blood-2010-12-326058 · Cited by 98
Molecular genetics and cellular events of K-Ras-driven tumorigenesis
Jinesh, G. G., Sambandam, V., Vijayaraghavan, S., Balaji, K., & Mukherjee, S. (2017) · Oncogene · doi:10.1038/onc.2017.377 · Cited by 108
Glioma Formation in Neurofibromatosis 1 Reflects Preferential Activation of K-RAS in Astrocytes
Dasgupta, B., Li, W., Perry, A., & Gutmann, D. H. (2005) · Cancer Research · doi:10.1158/0008-5472.236.65.1 · Cited by 114
Kindler, T., Cornejo, M. G., Scholl, C., Liu, J., Leeman, D. S., Haydu, J. E., Fröhling, S., Lee, B. H., & Gilliland, D. G. (2008) · Blood · doi:10.1182/blood-2008-03-147587 · Cited by 95
Self-citationK-Ras V14I recapitulates Noonan syndrome in mice
Hernández-Porras, I., Fabbiano, S., Schuhmacher, A. J., Aicher, A., Cañamero, M., Cámara, J. A., Cussó, L., Desco, M., Heeschen, C., Mulero, F., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1418126111 · Cited by 96
Inherited predispositions and hyperactive Ras in myeloid leukemogenesis
Lauchle, J. O., Braun, B. S., Loh, M. L., & Shannon, K. (2006) · Pediatric Blood & Cancer · doi:10.1002/pbc.20644 · Cited by 94
“as there is no abnormal expansion of immature blast forms in either blood or marrow [52,53].”
BackgroundReilly, J. T. (2004) · British Journal of Haematology · doi:10.1111/j.1365-2141.2004.05236.x · Cited by 115
“Recently, Chan et al (2004) developed a mouse model in which expression of oncogenic K-RAS resulted in a myeloproliferative disease rather than AML.”
BackgroundOncogenic NRAS rapidly and efficiently induces CMML- and AML-like diseases in mice
Parikh, C., Subrahmanyam, R., & Ren, R. (2006) · Blood · doi:10.1182/blood-2004-08-009498 · Cited by 93
Inactivating Icmt ameliorates K-RAS–induced myeloproliferative disease
Wahlstrom, A. M., Cutts, B. A., Liu, M., Lindskog, A., Karlsson, C., Sjogren, A.-K. M., Andersson, K. M. E., Young, S. G., & Bergo, M. O. (2008) · Blood · doi:10.1182/blood-2007-06-094060 · Cited by 91
EWS/FLI-1 Induces Rapid Onset of Myeloid/Erythroid Leukemia in Mice
Torchia, E. C., Boyd, K. L., Rehg, J. E., Qu, C., & Baker, S. J. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.00099-07 · Cited by 104
“Mice carrying a floxed K-ras allele and Mx1-cre transgene succumb to myeloproliferative disease with a latency of 35 days after pIpC treatment (14).”
BackgroundMethodResultFocus on myeloproliferative diseases and myelodysplastic syndromes
Etten, R. A. V., & Shannon, K. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.12.004 · Cited by 93
A MEK Inhibitor Abrogates Myeloproliferative Disease in Kras Mutant Mice
Lyubynska, N., Gorman, M. F., Lauchle, J., Hong, W. X., Akutagawa, J., Shannon, K., & Braun, B. S. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3001069 · Cited by 92
Prognostic impact of RAS-pathway mutations in patients with myelofibrosis
Santos, F. P. D. S., Getta, B. M., Masárová, L., Famulare, C. A., Schulman, J., Datoguia, T. S., Puga, R., Paiva, R. D. M. A., Arcila, M. E., Hamerschlak, N., et al. (2019) · Leukemia · doi:10.1038/s41375-019-0603-9 · Cited by 94
Polycomb complexes PRC1 and their function in hematopoiesis
Vidal, M., & Starowicz, K. (2017) · Experimental Hematology · doi:10.1016/j.exphem.2016.12.006 · Cited by 97
The transcription factor FOXL2: At the crossroads of ovarian physiology and pathology
Caburet, S., Georges, A. B., L’Hôte, D., Todeschini, A., Benayoun, B. A., & Veitia, R. A. (2011) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2011.06.019 · Cited by 99
“…the long-term physiological and molecular impact of p.C134W homologous mutation in the mouse, it would be interesting to create an inducible tissue specific knock-in mouse model, much like the one that has been described for the oncogenic mutation p.G12D of the K-Ras gene (Chan et al., 2004).”
Oncogenic NRAS, KRAS, and HRAS Exhibit Different Leukemogenic Potentials in Mice
Parikh, C., Subrahmanyam, R., & Ren, R. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0778 · Cited by 79
“Expression of oncogenic KRAS in a conditional knock-in mouse strain has been shown to exclusively induce a CMML-like disease (17, 18).”
BackgroundMelo-Cardenas, J., Xu, Y., Wei, J., Tan, C., Kong, S., Gao, B., Montauti, E., Kirsammer, G., Licht, J. D., Yu, J., et al. (2018) · Blood · doi:10.1182/blood-2017-10-811760 · Cited by 84
Converging pathways in leukemogenesis and stem cell self-renewal
Moore, M. A. S. (2005) · Experimental Hematology · doi:10.1016/j.exphem.2005.04.011 · Cited by 92
“Conditional expression of K-ras in a murine model led to development of a completely penetrant myeloproliferative syndrome characterized by leukocytosis with normal maturation of myeloid lineage cells, myeloid hyperplasia in the marrow, and extramedullary hematopoiesis [203].”
BackgroundVelasco-Hernandez, T., Säwén, P., Bryder, D., & Cammenga, J. (2016) · Stem Cell Reports · doi:10.1016/j.stemcr.2016.06.002 · Cited by 79
“This KRAS model has previously been shown to associate with a relatively high level of spontaneous activation when crossed to Mx1-Cre mice (Chan et al., 2004; Sabnis et al., 2009).”
BackgroundRowland, S. L., DePersis, C. L., Torres, R. M., & Pelanda, R. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20091673 · Cited by 74
“Chimeric mice were analyzed at 3 wk after transfer to limit tumor development caused by the expression of the constitutively active Ras oncogene (Braun et al., 2004; Chan et al., 2004).”
BackgroundGfi1 integrates progenitor versus granulocytic transcriptional programming
Horman, S. R., Velu, C. S., Chaubey, A., Bourdeau, T., Zhu, J., Paul, W. E., Gebelein, B., & Grimes, H. L. (2009) · Blood · doi:10.1182/blood-2008-09-179747 · Cited by 74
Rce1 deficiency accelerates the development of K-RAS–induced myeloproliferative disease
Wahlstrom, A. M., Cutts, B. A., Karlsson, C., Andersson, K. M. E., Liu, M., Sjogren, A.-K. M., Swolin, B., Young, S. G., & Bergo, M. O. (2007) · Blood · doi:10.1182/blood-2006-05-024752 · Cited by 72
Runx3 at the interface of immunity, inflammation and cancer
Lotem, J., Levanon, D., Negreanu, V., Bauer, O., Hantisteanu, S., Dicken, J., & Groner, Y. (2015) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2015.01.004 · Cited by 79
Alawieh, D., Cysique-Foinlan, L., Willekens, C., & Renneville, A. (2024) · Blood Cancer Journal · doi:10.1038/s41408-024-01054-2 · Cited by 75
“…Ras mutations exhibit variable behavior, for instance, the induction of heterozygous Kras G12D/ + expression in the hematopoietic system alone through Mx1-Cre leads to a rapid and highly penetrant myeloproliferative disease (MPD) modeling human MDS/MPN, but does not lead to AML progression [25].”
BackgroundXu, D., Wang, S., Yu, W., Chan, G., Araki, T., Bunting, K. D., Neel, B. G., & Qu, C. (2010) · Blood · doi:10.1182/blood-2010-01-265652 · Cited by 75
Niimi, H., Harada, H., Harada, Y., Ding, Y., Imagawa, J., Inaba, T., Kyo, T., & Kimura, A. (2006) · Leukemia · doi:10.1038/sj.leu.2404136 · Cited by 69
Harnessing preclinical mouse models to inform human clinical cancer trials
Gutmann, D. H., Hunter‐Schaedle, K., & Shannon, K. (2006) · Journal of Clinical Investigation · doi:10.1172/jci28271 · Cited by 72
Omidvar, N., Kogan, S. C., Beurlet, S., Pogam, C. L., Janin, A., West, R., Noguera, M., Reboul, M., Soulié, A., Lebœuf, C., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0196 · Cited by 68
“(34, 43 ). The last two models are particularly elegant in that despite the physiologic levels of mutant KRAS driven by its own promoter, alone a lethal disease ensues rapidly due to the Mx1 targeting a different progenitor to the MRP8-driven NRASD12 used in our present study.”
BackgroundDail, M., Li, Q., McDaniel, A., Wong, J., Akagi, K., Huang, B., Kang, H. C., Kogan, S. C., Shokat, K., Wolff, L., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1001064107 · Cited by 63
“To test this idea, we exploited the fact that the Kras G12D -induced MPD is not transplantable into sublethally irradiatedmice(23,24) andtransferred bonemarrowcells from48 moribund Kras G12D mice into 3 – 5 recipients that received 450 cGy of radiation (Fig.”
Oncogenic K-ras cooperates with PML-RAR to induce an acute promyelocytic leukemia-like disease
Chan, I. T., Kutok, J. L., Williams, I. R., Cohen, S., Moore, S., Shigematsu, H., Ley, T. J., Akashi, K., Beau, M. M. L., & Gilliland, D. G. (2006) · Blood · doi:10.1182/blood-2006-04-015040 · Cited by 67
Self-citationHoshii, T., Kasada, A., Hatakeyama, T., Ohtani, M., Tadokoro, Y., Naka, K., Ikenoue, T., Ikawa, T., Kawamoto, H., Fehling, H. J., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1320265111 · Cited by 66
NrasG12D/+ promotes leukemogenesis by aberrantly regulating hematopoietic stem cell functions
Wang, J., Kong, G., Liu, Y., Du, J., Chang, Y., Tey, S.-R., Zhang, X., Ranheim, E. A., Saba-El-Leil, M. K., Meloche, S., et al. (2013) · Blood · doi:10.1182/blood-2012-12-475863 · Cited by 67
Xiao, W., Ando, T., Wang, H., Kawakami, Y., & Kawakami, T. (2010) · Blood · doi:10.1182/blood-2010-05-283937 · Cited by 70
“STAT5 and other signaling pathways are activated by the TEL/PDGF R fusion protein in CMML patients with the t(5;12) (q33;p13) chromosomal translocation, and STAT5 is critical for this MPN.”
BackgroundMolecular pathogenesis of atypical CML, CMML and MDS/MPN-unclassifiable
Zoi, K., & Cross, N. C. P. (2014) · International Journal of Hematology · doi:10.1007/s12185-014-1670-3 · Cited by 67
“The most frequent mutations in KRAS and NRAS genes occur at codons 12, 31 and 61 [29–31].”
BackgroundWiemels, J. L., Zhang, Y., Chang, J. S.-M., Zheng, S., Metayer, C., Zhang, L., Smith, M. T., Ma, X., Selvin, S., Buffler, P. A., et al. (2005) · Leukemia · doi:10.1038/sj.leu.2403641 · Cited by 61
Loh, M. L., & Mullighan, C. G. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1936 · Cited by 65
“develop fatal myeloid disorders that resemble JMML in vivo and in vitro (67, 68).”
BackgroundModelling oncogenic Ras/Raf signalling in the mouse
Karreth, F. A., & Tuveson, D. A. (2009) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2008.12.006 · Cited by 59
Self-citationKratz, C. P., Schubbert, S., Bollag, G. E., Niemeyer, C. M., Shannon, K., & Zenker, M. (2006) · Cell Cycle · doi:10.4161/cc.5.15.3128 · Cited by 61
Dvorak, C. C., & Loh, M. L. (2014) · Frontiers in Pediatrics · doi:10.3389/fped.2014.00025 · Cited by 59
Gough, D. J., Marié, I. J., Lobry, C., Aifantis, I., & Levy, D. E. (2014) · Blood · doi:10.1182/blood-2013-02-484196 · Cited by 57
“Poly(I:C)-injected Mx-1–Cre:K-RasLSL:STAT3-LoxP/1 mice (referred to as Mx:K-Ras:F/1) are expected to develop MPNs with shared characteristics of JMML, including expansion of myeloid progenitors in the marrow and periphery, splenomegaly, and extramedullary hematopoiesis.(22,32) Induction of Mx-Cre effectively deleted t…”
BackgroundGarama, D. J., Harris, T. J., White, C. L., Rossello, F. J., Abdul-Hay, M., Gough, D. J., & Levy, D. E. (2015) · Molecular and Cellular Biology · doi:10.1128/mcb.00541-15 · Cited by 55
Mouse Models of Human Non-Small-Cell Lung Cancer: Raising the Bar
KIM, C. F. B., JACKSON, E. L., KIRSCH, D. G., GRIMM, J., SHAW, A. T., LANE, K., KISSIL, J., OLIVE, K. P., SWEET-CORDERO, A., WEISSLEDER, R., et al. (2005) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2005.70.037 · Cited by 58
Self-citationHematopoiesis and RAS-driven myeloid leukemia differentially require PI3K isoform p110α
Gritsman, K., Yuzugullu, H., Von, T., Yan, H., Clayton, L., Fritsch, C., Maira, S.-M., Hollingworth, G., Choi, C., Khandan, T., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci69927 · Cited by 55
“It was previously demonstrated that BM cells from KMX mice are able to form myeloid colonies in the absence of growth factors (38, 39).”
Influential
Metadata
- Authors
- Chan, I. T., Kutok, J. L., Williams, I. R., Cohen, S., Kelly, L., Shigematsu, H., Johnson, L., Akashi, K., Tuveson, D. A., Jacks, T., & Gilliland, D. G.
- Affiliations
- Brigham and Women's Hospital (US)
- Emory University (US)
- Harvard University (US)
- Dana-Farber Cancer Institute (US)
- Exelixis (United States) (US)
- Abramson Cancer Center (US)
- Howard Hughes Medical Institute (US)
- Corresponding author
- Gilliland, D. Gary
- Venue
- Journal of Clinical Investigation
- Published
- 2004-02-15
- Volume
- 113
- Issue
- 4
- Pages
- 528-538
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC338267
- OpenAlex
- W2147839086
- Cited by
- 270
- References
- 73
- Citations by year
- 2026: 3 · 2025: 5 · 2024: 4 · 2023: 3 · 2022: 3 · 2021: 9 · 2020: 3 · 2019: 8 · 2018: 8 · 2017: 12 · 2016: 9 · 2015: 10 · 2014: 13 · 2013: 16 · 2012: 12
- FWCI
- 14.27
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Howard Hughes Medical Institute
- Leukemia and Lymphoma Society
- National Institutes of Health (CA66996)
- National Cancer Institute (#CA66996, P01CA066996)
- National Institute of Diabetes and Digestive and Kidney Diseases (DK51564)
- Topics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and Retrovirus Studies
- Keywords
- oncogenic KRAS, endogenous promoter, conditional alleles, Cre-mediated recombination, myeloproliferative neoplasms, acute myeloid leukemia, hematopoietic system, myeloid hyperplasia, extramedullary hematopoiesis, cooperating mutations, RAS inhibitors, gene dosage
- MeSH terms
- Adenoma, Alleles, Animals, Bone Marrow Cells, Cells, Cultured, Hematopoietic Stem Cells, Humans, Mice, Inbred Strains, Mice, Transgenic, Myeloproliferative Disorders, Neoplasms, Papilloma, Phenotype, Promoter Regions, Genetic, Genes, ras, Leukemia, Myeloid, Acute, Gene Expression Regulation, Neoplastic, Bone Marrow Transplantation, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.